Point72 Asset Management L.P. Reduces Position in LivaNova PLC (NASDAQ:LIVN)

Point72 Asset Management L.P. trimmed its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 50.5% during the fourth quarter, Holdings Channel reports. The fund owned 1,036,248 shares of the company’s stock after selling 1,055,762 shares during the quarter. Point72 Asset Management L.P.’s holdings in LivaNova were worth $47,989,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Russell Investments Group Ltd. increased its stake in shares of LivaNova by 17.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after buying an additional 219 shares during the last quarter. Sterling Capital Management LLC increased its stake in shares of LivaNova by 800.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock worth $75,000 after buying an additional 1,441 shares during the last quarter. Vestcor Inc bought a new stake in shares of LivaNova in the fourth quarter worth $204,000. Optimize Financial Inc bought a new stake in shares of LivaNova in the fourth quarter worth $208,000. Finally, Corton Capital Inc. bought a new stake in shares of LivaNova in the fourth quarter worth $214,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Price Performance

Shares of NASDAQ:LIVN opened at $43.82 on Friday. The company has a market cap of $2.39 billion, a PE ratio of 104.33 and a beta of 0.84. The firm has a 50-day simple moving average of $38.28 and a 200 day simple moving average of $44.96. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $63.57.

Wall Street Analyst Weigh In

Several brokerages have recently commented on LIVN. Barclays reduced their price target on shares of LivaNova from $56.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Thursday, May 8th. StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 8th. The Goldman Sachs Group reduced their price target on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. Stifel Nicolaus dropped their price target on LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reissued a “buy” rating and set a $64.00 price target on shares of LivaNova in a research report on Tuesday. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $59.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.